Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
6.50
Oct 22 • 3:59 PM ET Dollar change-0.01 Percentage change(-0.15%)
Aftermarket Close
6.50
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Oct 21, 9:05 AMAchieve Life Sciences announces positive 52-week ORCA-OL trial results showing sustained smoking and vaping cessation and no new safety signals for cytisinicline.
Index
RUT
Market Cap
668.87M
Enterprise Value
496.52M
Income
-114.04M
Sales
0.00M
Book/sh
-0.14
Cash/sh
1.82
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
28
IPO
Oct 12, 1995
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
3.57
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
0.95
Current Ratio
0.95
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-1.55
EPS next Y
-0.68
EPS next Q
-0.20
EPS this Y
-16.80%
EPS next Y
53.58%
EPS next 5Y
-
EPS past 3/5Y
32.06% 25.38%
Sales past 3/5Y
- -
EPS Y/Y TTM
-6.14%
Sales Y/Y TTM
-
EPS Q/Q
-118.05%
Sales Q/Q
-
Insider Own
32.16%
Insider Trans
-0.06%
Inst Own
56.43%
Inst Trans
52.08%
ROA
-91.46%
ROE
-844.99%
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-8.61%
SMA50
-14.07%
SMA200
16.03%
Trades
Shs Outstand
102.72M
Shs Float
69.81M
52W High
8.64 -24.77%
52W Low
2.62 148.09%
Volatility
6.77% 5.83%
ATR (14)
0.40
RSI (14)
36.57
Beta
2.40
Rel Volume
0.67
Avg Volume
1.44M
Volume
963,324
Perf Week
-6.74%
Perf Month
-16.99%
Perf Quarter
6.56%
Perf Half Y
56.63%
Perf YTD
30.78%
Perf Year
27.20%
Perf 3Y
62.50%
Perf 5Y
-18.95%
Perf 10Y
-99.27%
Prev Close
6.51
Price
6.50
Change %
-0.15%
Date Action Analyst Rating Change Price Target Change
Sep-30-26Initiated Stifel Buy $18
Aug-13-26Initiated Morgan Stanley Overweight $13
Jun-26-26Resumed Raymond James Strong Buy $20
Apr-21-26Initiated Canaccord Genuity Buy $13
Nov-25-25Initiated Citizens JMP Mkt Outperform $19
Aug-21-25Initiated H.C. Wainwright Buy $12
Nov-14-24Initiated Rodman & Renshaw Buy $12
Sep-27-24Initiated Raymond James Strong Buy $20
May-10-23Reiterated Maxim Group Buy $8 → $20
Jun-23-21Initiated Oppenheimer Outperform $23
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stewart Richard AlistairDirectorAug 19 '26Sale8.4920,626175,177208,249Aug 21 04:30 PM
Stewart Richard AlistairDirectorAug 19 '26Proposed Sale7.5220,626155,108Aug 19 09:16 AM
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.
Chief Legal OfficerMr. Erik Atkisson
CEODr. Andrew D. Goldberg M.D.
Chief Financial OfficerMr. Benjamin Halladay M.B.A.
VP of Finance & Principal Accounting OfficerMr. Jerry Wan
Senior Vice President of Marketing & CommunicationsMs. Kaitlyn Tuson